PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-415-08

Reported: January 1, 2025 Initiated: December 6, 2024 #D-0158-2025

Product Description

Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-415-08

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Details

Units Affected
1,815 bottles
Distribution
Nationwide in the USA
Location
Columbus, OH

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-415-08. Recalled by Amerisource Health Services LLC. Units affected: 1,815 bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 1, 2025. Severity: Moderate. Recall number: D-0158-2025.